MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Emergent BioSolutions Inc

Открыт

СекторЗдравоохранение

9.31 2.42

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

9.02

Макс.

9.33

Ключевые показатели

By Trading Economics

Доход

-80M

-12M

Продажи

-81M

141M

P/E

Средняя по отрасли

3.399

35.739

Рентабельность продаж

-8.517

Сотрудники

900

EBITDA

-131M

1.6M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+28.73% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

154M

477M

Предыдущая цена открытия

6.89

Предыдущая цена закрытия

9.31

Новостные настроения

By Acuity

7%

93%

5 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Emergent BioSolutions Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 окт. 2025 г., 23:30 UTC

Популярные акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 окт. 2025 г., 21:21 UTC

Отчет

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 окт. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 окт. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 окт. 2025 г., 23:39 UTC

Обсуждения рынка

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 окт. 2025 г., 23:00 UTC

Обсуждения рынка

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Scales's JV Buyout Lauded by Bull -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Forex and Fixed Income Roundup: Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 окт. 2025 г., 21:17 UTC

Приобретения, слияния, поглощения

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Energy & Utilities Roundup: Market Talk

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

2 окт. 2025 г., 20:49 UTC

Приобретения, слияния, поглощения

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 окт. 2025 г., 20:00 UTC

Приобретения, слияния, поглощения

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 окт. 2025 г., 19:20 UTC

Обсуждения рынка

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 окт. 2025 г., 19:10 UTC

Обсуждения рынка

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 окт. 2025 г., 19:04 UTC

Обсуждения рынка

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 окт. 2025 г., 18:43 UTC

Приобретения, слияния, поглощения

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение c конкурентами

Изменение цены

Emergent BioSolutions Inc Прогноз

Целевая цена

By TipRanks

28.73% рост

Прогноз на 12 месяцев

Средняя 11.83 USD  28.73%

Максимум 15 USD

Минимум 8.5 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Emergent BioSolutions Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

4.95 / N/AПоддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

5 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat